Trial Profile
Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Endometrial cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Genmab; Seagen
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 06 Jan 2018 This study has been completed in Belgium (End date: 2017-12-13)
- 22 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.